Skip to main content

Advertisement

Table 2 Clinical characteristics of 7 patients with diffuse large B cell lymphoma

From: Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Characteristic n (%)
Middle Age (range) 34 years old (18-50)
Gender  
 Male 1 (14.3)
 Female 6 (85.7)
Clinical staging  
 II 2 (28.6)
 IV 5 (71.4)
Performance status score (Eastern Cooperative Oncology Group)  
 0 5 (71.4)
 1 1 (14.3)
 2 1 (14.3)
International prognostic index  
 0-1 1 (14.3)
 2 4 (57.1)
 3 2 (28.6)
Bulky disease (longest diameter ≥ 7.5 cm by CT scan)  
 Mediastinum 5 (71.4)
 Abdominal cavity 2 (28.6)
B symptoms  
Weight lose 2 (28.6)
Fever 1 (14.3)
Laboratory abnormalities  
 LDH (>240 IU/L) 6 (85.7)
 C-reactive protein increased 6 (85.7)